ATAI Life Sciences Acquires Majority Stake in Kures
July 9, 2020
ATAI Life Sciences AG acquired a majority stake in New York–based pharmaceutical company Kures to advance Kures' mitragynine-derived therapeutic candidates (KUR-101 and KUR-002) targeting pain and opioid use disorder. The deal brings Kures onto ATAI's biotech platform and appoints ATAI CSO Srinivas Rao as Kures CEO to accelerate development and integrate the assets into ATAI's mental-health-focused pipeline.
- Buyers
- ATAI Life Sciences AG
- Targets
- Kures
- Industry
- Biotechnology
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.